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ABSTRACT
The fetal isoform A of the insulin receptor (IR-A) is frequently overexpressed in 
a variety of malignancies including breast cancer. IR overexpression has a recognized 
role in cancer progression and resistance to anticancer therapies. In particular, IR-A 
has a peculiar mitogenic potential and is activated not only by insulin but also by IGF-2. 
Previously, we identified discoidin domain receptor 1 (DDR1) as a new IR-A interacting 
protein. DDR1, a non-integrin collagen tyrosine kinase receptor, is overexpressed in 
several malignancies and plays a role in cancer progression and metastasis.
We now evaluated whether DDR1 is able to exert a role in breast cancer biology 
by functionally cross-talking with IR. In MCF-7 human breast cancer cells, IR and 
DDR1 co-immunoprecipitated and co-localized after insulin or IGF-2 stimulation. 
In a panel of breast cancer cells, DDR1 knockdown by specific siRNAs markedly 
inhibited IR downstream signaling as well as proliferation, migration and colony 
formation in response to insulin and IGF-2. These effects were accompanied by 
reduction of IR protein and mRNA expression, which involved both transcriptional 
and post-transcriptional effects. DDR1 overexpression elicited opposite effects. 
Bioinformatics analysis of public domain databases showed that IR and DDR1 co-
expression significantly correlates with several clinically relevant histopathological 
and molecular features of human breast carcinomas.
These findings demonstrate that, in human breast cancer cells, DDR1 regulates 
IR expression and ligand dependent biological actions. This novel functional crosstalk 
is likely clinically relevant and may become a new molecular target in breast cancer.
INTRODUCTION
Dysregulation of the insulin/IGF signaling (IIGFs), 
involving the overexpression of receptors for IGF-1 and/
or insulin (IGF-1R and IR) and/or cognate ligands (IGF-
1, IGF-2), has an important role in the early phases of 
carcinogenesis of breast cancer, and is associated with 
cancer progression and metastases and resistance to a 
variety of therapies [1–4]. IIGFs is especially relevant 
to Epithelial Mesenchymal Transition (EMT) [5] and 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 26), pp: 43248-43270
Research Paper
Oncotarget43249www.impactjournals.com/oncotarget
other stem-like features [6], which play a key role in 
cancer development and recurrence. However, IGF-1R 
inhibitors have shown limited benefit in cancer when used 
as single therapy [7–10]. Thus, to exploit the anticancer 
potential of IIGFs inhibition, there is an urgent need to 
better understand IIGFs activities and interactions. A 
deep understanding of the molecular mechanisms for this 
failure will open the way to successful therapies able to 
eradicate breast cancer. A major mechanism of resistance 
to anti-IGF-1R drugs involves the IR, which is commonly 
overexpressed in breast cancer and predominantly 
expressed as the so called ‘fetal isoform’ (IR-A), which 
is a bona fide receptor for IGF-2 and proinsulin [11, 12]. 
Significantly, the IR-A/IGF-2 autocrine loop plays a key 
role in many cancer histotypes, including breast cancer 
[13, 14].
Notably, IRs and IGF-1R signaling and actions 
may undergo diversification following crosstalk with 
other membrane receptors. In a previous study, aimed at 
discovering new substrates/mediators of the IGF-2/IR-A 
pathway, we reported that DDR1 is found in multiprotein 
complexes associated with tyrosine-phosphorylated IR in 
response to IGF-2 and to a lesser extent to insulin [15]. 
DDR1 belongs to the discoidin domain receptors (DDRs), 
family, which includes two members, DDR1 and DDR2 
recognized as collagen receptors [16, 17]. Upon binding 
to collagens, DDR1 undergoes slow but prolonged 
phosphorylation at several tyrosine residues, which 
potentially serve as binding sites of Src-homology-2 
(SH2) and phosphotyrosine binding (PTB) domain-
containing molecules [18]. DDR1 is often overexpressed 
in cancer, and plays a critical role in cancer cell migration, 
EMT, and metastases [19–22]. We recently reported that, 
in breast cancer cells, IGF-1R functionally crosstalks with 
DDR1 and this interaction increases IGF-1R stability 
and enhances protumorigenic actions of IGF-1 [23]. In 
turn, IGF-1, as well as IGF-2 and insulin, induce DDR1 
upregulation and activation establishing a positive 
feedback of IIGFs [24].
In the present work we aimed at elucidating the 
biological role of the IR - DDR1 crosstalk in human breast 
cancer cells. These results indicate that this functional 
interaction plays a significant role in human breast cancer 
and may become a viable target for therapy.
RESULTS
DDR1 and IR expression in breast cancer cells
We first evaluated by immunoblot the expression of 
DDR1 and IR in a panel of human breast cancer cell lines 
(MCF-7, T47D, ZR-75, BT-474, MDA-MB-157, MDA-
MB-231, MDA-MB-468). Both molecules were expressed 
at variable levels with the highest DDR1 levels observed 
in MCF-7, T47D, ZR-75, BT-474 and MDA-MB-468, 
and the highest IR levels observed in MCF-7, ZR-75 and 
MDA-MB-157 cells (Figure 1a). DDR1 and IR mRNA 
expression, measured by quantitative real-time RT-PCR 
(qRT–PCR), was generally in good agreement with the 
immunoblot results (Figure 1b).
MCF-7, BT-474 and MDA-MB-157 breast cancer 
cells were chosen for subsequent experiments. All these 
cells have ductal characteristics and metastatic potential, 
and all respond to insulin [25]. MCF-7 and BT-474 are 
estrogen receptor positive, while MDA-MB-157 cells 
have characteristics of triple negative cells. BT-474 cells 
are also HER-2 positive and tamoxifen-resistant. Both 
MCF-7 and BT-474 cells expressed high levels of DDR1 
and IR, with MCF-7 expressing higher IR levels than 
BT-474. MDA-MB-157 showed low levels of DDR1 and 
intermediate levels of IR. The IGF-1R was expressed at 
high levels in MCF-7 cells, low levels in MDA-MB-157 
and intermediate levels in BT-474 cells (Figure 1a).
DDR1 and IR interact in breast cancer cells
In order to evaluate whether the DDR1 and IR co-
localize in breast cancer cells, MCF-7 cells were plated 
onto coverslips, serum-starved for 24h and stimulated 
with either insulin or IGF-2 at a dose of 10nM for 5 and 
20 min. Cells were then stained with anti-DDR1 and anti-
IR antibodies and examined by confocal microscopy. In 
unstimulated cells, IR and DDR1 were mainly expressed 
at the plasma membrane with minimal co-localization 
observed. After cell stimulation with either insulin 
(Figure 2a, upper panel) or IGF-2 (Figure 2a, lower 
panel), both IR and DDR1 were rapidly internalized 
and co-localized in both the cytoplasm and perinuclear 
compartments. These results were confirmed by co-
immunoprecipitation. MCF-7 cells were serum starved, 
treated or not with either insulin or IGF-2 (10nM for 
5min), lysed and immunoprecipitated with anti-DDR1 
antibody. Immunoprecipitates were then blotted with 
either anti-DDR1 or anti-IR antibodies, respectively 
(Figure 2b). DDR1 co-precipitated with the IR and 
this interaction was enhanced after insulin and IGF-2 
stimulation (Figure 2b).
DDR1 expression levels regulate insulin and 
IGF-2 biological effects
We next evaluated whether DDR1 expression could 
modulate the biological effects of insulin and IGF-2 in 
breast cancer cells. Indeed, in all three breast cancer 
cell lines, MCF-7, MDA-MD-157 and BT-474, DDR1 
silencing by a pool of four specific siRNA oligos (Figure 
3a) was associated with marked inhibition of cell viability 
as assessed by the MTT assay (Figure 3b) and cell cycle 
progression (Figure 3c), both in unstimulated cells and 
after treatment with either insulin or IGF-2. DDR1 
silencing additionally inhibited other protumorigenic 
actions of insulin and IGF-2, such as cell invasion 
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Figure 1: IR, DDR1 and IGF-1R expression in cultured cells. (a) DDR1, IR and IGF-1R protein expression in various cell lines. 
A panel of human breast cancer cell lines (MCF-7, T47-D, ZR-75, BT-474, MDA-MB-157, MDA-MB-231, MDA-MB-468) were analyzed 
by western immunoblot for DDR1, IR and IGF-1R expression using specific polyclonal antibodies, as indicated. β-actin antibody was 
used as control for protein loading. A representative blot of three independent experiments is shown. (b) qRT-PCR analysis of DDR1 and 
IR mRNA. Human DDR1 and IR mRNA levels were evaluated in all human cell lines shown in panel (a). Normalization was done using 
human β-actin as housekeeping control gene. Data are presented as the mean±SEM (error bars) from three independent experiments.
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Figure 2: IR and DDR1 co-localization. (a) IR and DDR1 co-localize in breast cancer cells. MCF-7 cells were plated onto coverslips 
and serum-starved for 6h. Cells were then stimulated with 10nM of either insulin (upper panel) or IGF-2 (lower panel) for the indicated 
times. The staining indicating co-localization of the IR with DDR1 was assessed by confocal microscopy. Graphs on the right showing 
the co-localization index, calculated by ImageJ software, represent the mean±SEM of two independent experiments. (b) IR and DDR1 co-
immunoprecipitate in MCF-7 breast cancer cells. Insulin and IGF-2 stimulation increases IR co-immunoprecipitation with DDR1. Cells 
were serum starved for 24h and stimulated with either insulin or IGF-2 (10nM) for 5min. Cells were then solubilized and total lysates were 
(C1). Immunoprecipitated with anti-DDR1 specific antibody. Negative control, including the use of an unrelated primary antibody, is also 
shown. An aliquot of each fraction (input) was evaluated as control. Filters were probed with anti-DDR1 or anti-IR antibodies, as indicated. 
A representative blot of three independent experiments is shown. The graph on the right represents the mean±SEM of the densitometric 
analysis where IR signal was normalized against total DDR1. (a-b) *0.01 < p < 0.05; **0.001 < p < 0.01; (basal vs. insulin or IGF-2). 
Statistical significance was calculated using Student’s t-test.
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Figure 3: DDR1 depletion affects insulin and IGF-2 mediated biological effects in human cancer cells. (a) Western blot 
before and after DDR1 depletion. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were transiently transfected with either a pool 
of four DDR1 siRNA oligos or scramble siRNA oligos. After 24h, cells were grown in medium containing 2.5% of CS-FCS for 24h. 
DDR1 depletion was confirmed for each cells line by western blot analysis as shown in the panel. (b) Cell proliferation. Cell viability was 
evaluated by MTT assay. Values are expressed as percentages of untreated scramble-transfected cells (basal) and represent the mean±SEM 
of three independent experiments in triplicate. (c) Cell cycle progression. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were 
transiently transfected as in (a). After 24h, cells were grown in medium containing 0.1% of BSA for additional 24h. Cells were then 
incubated with or without insulin or IGF-2 at a dose of 10nM for additional 48h and analyzed for cell-cycle profiles. Cell populations 
positive for propidium iodine staining were evaluated by FACS analysis, and G0/G1 and G2/M phases were scored. The graph shows 
the percentage of cells in S and G2/M phases. Values are expressed as percent of basal (untreated scramble transfected cells) and are the 
mean±SEM of three independent experiments. 
(Continued )
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Figure 3: (Continued ) (d) Cell invasion. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were transiently transfected as in (a). 
After 24h, cells were grown in medium containing 0.1% of BSA for additional 24 h. Cells were then removed from plates with 0.01% trypsin 
and seeded on polycarbonate filters coated with 25μg/mL fibronectin. Cells were allowed to migrate for 6h (MCF-7 and MDA-MB-157) 
or 8h (BT-474 cells) in response to 10nM of insulin or IGF-2 added to the lower chamber. Values are mean±SEM of three independent 
experiments done in duplicate and are expressed as percent increase over untreated scramble cells (basal). (e) Colony formation. MCF-7, 
MDA-MB-157 and BT-474 breast cancer cells were transiently transfected as in (a), and seeded in soft-agar, as described in Materials and 
Methods. Cells were plated in triplicate and cultured in serum free medium containing 2.5% CS-FCS for 3 weeks. Colonies developed only 
from plated MCF-7 and MDA-MB-157 cells but not from BT-474. Colonies were stained with MTT and then photographed. The histogram 
represents the mean number of colonies shown in (e). Error bars indicate SEM (n = 3 wells). (b-e) *0.01 < p < 0.05; **0.001 < p < 0.01; 
***p < 0.001. Statistical significance was calculated using one-way ANOVA followed by Bonferroni test.
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through fibronectin-coated filters (Figure 3d) and colony 
formation in semi-solid agar (Figure 3e). Accordingly, 
transient DDR1 overexpression (Figure 4a) enhanced cell 
viability (Figure 4b), cell cycle progression (Figure 4c), 
cell invasion (Figure 4d), and colony formation (Figure 
4e), both in unstimulated cells and after stimulation with 
either insulin or IGF-2. In our experimental conditions, 
BT-474 cells did not form colonies in soft agar with 
charcoal-stripped serum-containing media.
Noteworthy, all these experiments were carried out 
in the absence of collagen, indicating that this modulation 
of insulin and IGF-2 effects is independent of DDR1 
function as a collagen receptor.
DDR1 is a critical regulator of IR expression and 
downstream signaling
As DDR1 regulates IR biological actions, we 
evaluated whether DDR1 regulated IR expression levels 
and/or IR intracellular signaling after ligand stimulation. 
Indeed, DDR1 silencing by a pool of four specific 
siRNA oligos significantly reduced the expression of 
IR protein and mRNA (Figure 5a) in all three cell lines 
tested. Conversely, transient DDR1 overexpression 
using a constitutive DDR1 encoding vector (pCMV6-
DDR1) resulted in significant increase of IR protein and 
mRNA levels (Figure 5b). The increase in IR protein 
expression was further confirmed transiently transfecting 
MCF-7, MDA-MB-157 and BT-474 cell lines with pTZ 
doxy-inducible lentiviral vector encoding for DDR1 
(Supplementary Figure 1). Accordingly, IR downstream 
signaling in response to insulin and IGF-2 stimulation was 
inhibited by DDR1 silencing (Figure 6a) and increased by 
DDR1 overexpression (Figure 6b). In particular, the two 
main IR downstream signaling cascades, the AKT and 
ERK1/2 pathways, were significantly affected by changes 
in DDR1 expression (Figure 6a and 6b).
Taken together these data indicate that DDR1 
modulates IR response to insulin and IGF-2 by regulating 
IR expression levels.
DDR1 regulates IR expression at multiple levels
As DDR1 enhanced both IR mRNA and protein 
expression levels, we explored the mechanisms 
responsible for this effect. We first evaluated 26S 
proteasome-dependent IR protein degradation. We found 
that the decrease in IR protein levels induced by DDR1 
silencing was partially reversed after treating MCF-7 
cells with the 26S proteasome inhibitor, MG132 (Figure 
7a). Next, we tested the contribution of the lysosomal 
degradation pathway by using the lysosomal inhibitor 
cloroquine. We found that, DDR1 levels were affected by 
cloroquine treatment in scramble-transfected cells, but not 
after DDR1 silencing (Figure 7b). Taken together, these 
results indicate that DDR1 affects the intracellular pool of 
IR protein degraded via proteasome but not by lysosomal 
degradation.
As DDR1 additionally affected the steady-state 
level of IR mRNA (Figure 5a and 5b), we asked whether 
translational and/or transcriptional mechanisms were 
involved. To this aim we studied MCF-7 cells at different 
time points after treatment with either the protein synthesis 
inhibitor cycloheximide or the transcriptional inhibitor 
actinomycin D. We found that cycloheximide significantly 
prolonged IR protein half-life in cells transiently 
overexpressing DDR1 as compared to control cells (EV 
transfected). Indeed, in DDR1 overexpressing cells IR 
up-regulation was not affected by 24h of cycloheximide 
treatment; in contrast, in control cells IR protein levels 
decreased to roughly 50% after 16h exposure to 
cycloheximide, suggesting that DDR1 increases IR protein 
by additionally affecting its de novo synthesis (Figure 7c). 
Similarly, actinomycin D treatment reduced IR mRNA 
more markedly in control cells (EV) than in DDR1-
transfected cells; after 4h exposure to the drug IR mRNA 
levels were 60% of basal in EV transfected cells vs. 20% 
in DDR1 overexpressing cells (Figure 7d).
We next evaluated whether DDR1 could affect 
the main factors involved in the regulation of IR gene 
transcription, namely Sp1 and HMGA1, that are positive 
regulators, or p53, that is instead a negative regulator [26, 
27]. Using MCF-7 cells, we found that IR down-regulation 
observed after DDR1 silencing was associated with 
significant reduction of Sp1 and HMGA1 proteins, and 
increased levels of p53 protein (Figure 8a). Conversely, 
IR upregulation observed after DDR1 transient 
overexpression was associated with opposite changes in 
Sp1, HMGA1 and p53 proteins (Figure 8b). The mRNA 
levels of these factors changed according to their protein 
expression profile both after DDR1 silencing (Figure 8c) 
or overexpression (Figure 8d). These data implicate DDR1 
as a regulator of key transcription factors involved in IR 
gene expression.
Taken together, all these data indicate that DDR1 
regulates IR expression at multiple levels by modulating 
protein degradation and stability, gene transcription and 
post-transcriptional mRNA regulation.
DDR1 and IR are positively correlated in human 
breast cancer specimens
In order to verify whether DDR1 and IR expression 
positively correlated in human breast cancer specimens 
we used a bioinformatic analysis. By computing Pearson 
correlation between three probes for DDR1 and IR, 
we obtained 228 Pearson values out of 288 possible 
combinations (60 Pearson values were not calculated 
because the probes were lacking for some datasets) 
(Supplementary Table 1). We found 99 statistically 
significant (p-value ≤0.05) positive Pearson values 
and 6 negative Pearson values. Interestingly, 6 datasets 
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Figure 4: DDR1 overexpression affects insulin and IGF-2 mediated biological effects in human cancer cells. (a) Western 
blot before and after DDR1 overexpression. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were transiently transfected with 
either constitutive empty (pCMV6-EV) or human DDR1 (pCMV6-DDR1) expressing vectors. After 24h, cells were grown in medium 
containing 2.5% of CS-FCS for 24h and then stimulated with 10nM of insulin or IGF-2. DDR1 overexpression was confirmed for each cells 
line by western blot analysis. (b) cell proliferation. Breast cancer cells were transfected as in (a). After 24h, cells were grown in medium 
containing 0.1% of BSA for additional 24h and then stimulated with 10nM of insulin or IGF-2 for 48h. Cell viability was evaluated by MTT 
assay. Values are expressed as percentages of empty vector-transfected cells (basal) and represent the mean±SEM of three independent 
experiments in triplicate. (c) Cell cycle progression. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were transiently transfected 
as in (a). After 24h, cells were grown in medium containing 0.1% of BSA for additional 24h. Cells were then incubated with or without 
insulin or IGF-2 at a dose of 10nM for additional 48h and analyzed for cell-cycle profiles. Cell populations positive for propidium iodine 
staining were evaluated by FACS analysis, and G0/G1 and G2/M phases were scored. The graph shows the percentage of cells in S and 
G2/M phases. Values are expressed as percent of basal (untreated scramble transfected cells) and are the mean±SEM of three independent 
experiments. 
(Continued )
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Figure 4: (Continued ) (d) Cell invasion. MCF-7, MDA-MB-157 and BT-474 breast cancer cells were transiently transfected as in 
(a). After 24h, cells were grown in medium containing 0.1% of BSA for additional 24h. Cells were then removed from plates with 0.01% 
trypsin and seeded on polycarbonate filters coated with 25μg/mL fibronectin. Cells were allowed to migrate for 6h (MCF-7 and MDA-
MB-157) or 8h (BT-474 cells) in response to 10nM of insulin or IGF-2 added to the lower chamber. Values are mean±SEM of three 
independent experiments done in duplicate and are expressed as percent of untreated scramble cells (basal). (e) Colony formation. MCF-7, 
MDA-MB-157 and BT-474 breast cancer cells were transiently transfected as in (a), were seeded in soft-agar, as described in Materials 
and Methods. Cells were plated in triplicate and cultured in serum free medium containing 2.5% CS-FCS for 3 weeks. Colonies developed 
only from MCF-7 and MDA-MB-157 cells and not from BT-474. Colonies were stained with MTT and then photographed. The histogram 
represents the mean number of colonies shown in (e). Error bars indicate SEM (n = 3 wells). (b-e) NS, *0.01 < p < 0.05; p > 0.05; **0.001 
< p < 0.01; ***p < 0.001; statistical significance was calculated using one-way ANOVA followed by Bonferroni test.
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Figure 5: DDR1 affects IR expression. (a) IR protein and mRNA expression in DDR1-depleted cells. MCF-7, MDA-MB-157 and 
BT-474 breast cancer cells were transiently transfected with either a pool of four scramble or four DDR1 siRNA oligos. After 48h, cells 
were lysed and analyzed by SDS-PAGE and immunoblotted with the indicated primary antibodies. β-actin was used as control for protein 
loading. Blot is representative of three independent experiments. The histograms represent the mean±SEM of densitometric analysis after 
normalization against β-actin. In the same transfected cell lines, IR mRNA levels were evaluated by qRT-PCR analysis and values were 
normalized using human β-actin as housekeeping control gene. In parallel, DDR1 mRNA was evaluated by qRT-PCR to confirm DDR1 
depletion (graphs on the right). 
(Continued )
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Figure 5: (Continued ) (b) IR protein and mRNA expression after DDR1 overexpression. Breast cancer cells were transiently 
transfected with either constitutive empty (pCMV6-EV) or human DDR1 (pCMV6-DDR1) expressing vectors. After 48h, cells were lysed, 
analyzed by SDS-PAGE and immunoblotted with the indicated primary antibodies. β-actin was used as control for protein loading. The top 
panels show a representative blot of three independent experiments. The histograms represent the mean±SEM of densitometric analysis 
after normalization over β-actin. In the same transfected cells, IR mRNA levels were evaluated by qRT-PCR analysis and values were 
normalized using human β-actin as housekeeping control gene. The overexpression of DDR1 was confirmed measuring DDR1 mRNA by 
qRT-PCR (graphs on the right). (a-b) *0.01 < p < 0.05; *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001; (scramble vs. siDDR1 and EV 
vs. DDR1 and transfected cells). statistical significance was calculated using Student’s t-test.
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Figure 6: DDR1 depletion or overexpression affects insulin and IGF-2 downstream signaling in human breast cancer 
cells. (a) Insulin and IGF-2 signaling after DDR1 depletion. MCF-7, BT-474 and MDA-MB-157 breast cancer cells were transiently 
transfected with a pool of four scramble or of four siRNA oligos against DDR1. After 48h, cells were grown in medium containing 2.5% 
of CS-FCS for 24h and then stimulated with or without 10nM of insulin or IGF-2 for 5 minutes. Cells were then lysed and analyzed by 
SDS-PAGE and immunoblotted with the indicated primary antibodies. β-actin was used as control for protein loading. The top panels show 
a representative of three experiments. The histograms represent the mean±SEM of densitometric analysis of three independent experiments 
after normalization of each phosphoprotein against β-actin. 
(Continued )
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Figure 6: (Continued ) (b) Insulin and IGF-2 signaling after DDR1 overexpression. MCF-7, BT-474 and MDA-MB-157 breast 
cancer cells were transiently transfected with plasmids encoding either the human DDR1 cDNA (pCMV6-DDR1) or the corresponding 
empty vector (pCMV6-EV). After 48h, cells were grown in medium containing 2.5% of CS-FCS for 24h and then stimulated with or 
without 10nM of insulin or IGF-2 for 5 minutes. The activation of downstream signaling was assessed as in (a). Blots are representative of 
three independent experiments. The histograms represent the mean±SEM of densitometric analysis of three independent experiments after 
normalization of each phosphoproteins against β-actin. (a-b) NS, p > 0.05; *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001; statistical 
significance was calculated using one-way ANOVA followed by Bonferroni test.
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(gse21618, gse42568, gse12276, gse21653, gse29271, 
gse76124) showed a persistent positive correlation 
between DDR1 and IR with all combinations of probes 
analyzed. Definitively, these computational data strongly 
suggested that a general positive correlation between 
DDR1 and IR transcripts exists in breast carcinoma 
(Supplementary Table 1).
For GEO datasets gse42568, gse21653, gse76124 
we found clinical and biological information useful to 
stratify the data, in order to verify whether DDR1-IR 
correlation is associated with bio-pathological features of 
patients (Figure 9A and 9B). This analysis showed that 
correlation of expression was more statistically significant 
in tumors with the following characteristics: 1) negative 
for ER; 2) negative for progesterone receptor; 3) basal-
like histology; 4) positive for pathological lymph nodes; 
5) positive for Ki-67 protein status; 6) pathological 
tumor size 3 (pT3); 7) grade 3 (G3). The correlations 
Figure 7: DDR1 stabilizes IR both at the protein and mRNA level in MCF-7 cells. (a) DDR1 depletion affects IR proteasomal 
degradation. MCF-7 cells were transiently transfected with either a pool of four scramble or four DDR1-specific siRNA oligos. After 48h, 
cells were treated with 1μM of the proteasome inhibitor MG132 for 6h. (b) DDR1 depletion does not affect IR lysosomal degradation. 
MCF-7 cells were transiently transfected as in (a). After 48 h, cells were treated with 10μM of the cloroquine (CHL) for 2, 6, and 24h. (c) 
Cycloheximide treatment in DDR1 overexpressing cells. MCF-7 cells were transiently transfected with either pCMV6-EV or pCMV6-DDR1 
encoding vectors. After 24 h, cells were treated with 100 μM of cycloheximide (CHX) for 8, 16, and 24h. (d) Actinomycin D treatment in 
DDR1 overexpressing cells. MCF-7 cells were transiently transfected as in (c). After 24h, cells were treated with 2.5μg/mL of actinomycin 
D (ACT D) for 2, 4, 6, and 16h. IR mRNA levels were evaluated by qRT-PCR analysis and values were normalized using human β-actin 
as housekeeping control gene. DDR1 overexpression was confirmed by western blot analysis as shown on the right of the histogram. (a-c) 
Samples were analyzed by western blotting for DDR1 and IR expression. β-actin antibody was used as control. A representative blot of three 
independent experiments is shown. The histogram represents the mean±SEM of densitometric analysis after normalization against β-actin. 
(a-d) NS, p > 0.05; *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001. Statistical significance was calculated using Student’s t-test.
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were statistically significant in both normal and tumor 
samples but p-values were considerably lower in the latter, 
especially in poorly differentiated tumors (Figure 9B).
DISCUSSION
Our present results demonstrate that in human 
breast cancer cells DDR1 is a signaling partner of 
the IR and a strong modulator of IR expression and 
biological responses. DDR1 and IR co-localize and co-
immunoprecipitate, especially after stimulation with either 
insulin or IGF-2. We also show that, after stimulation with 
insulin or IGF-2, DDR1 is rapidly internalized with the 
IR and co-localizes with the IR in the cytoplasm. These 
findings are reminiscent of similar data we previously 
observed with the IR-homolog IGF-1R [23]. Noteworthy, 
Figure 8: DDR1 affects IR – dependent transcription factors. (a) Protein levels of IR-dependent transcription factors after DDR1 
depletion. MCF-7 breast cancer cells were transiently transfected with either a pool of four scramble or four DDR1 specific siRNA oligos. 
After 48h, protein expression of IR, and of p53, HMGA, and Sp1 transcription factors was evaluated by western blotting. The histograms 
represent the mean±SEM of densitometric analysis of three independent experiments after normalization against β-actin. (b) Protein levels 
of IR-related transcription factors after DDR1 overexpression. MCF-7 cells were transiently transfected with either either pCMV6-EV 
or pCMV6-DDR1 encoding vectors. After 48h, protein expression of IR, p53, HMGA, and Sp1 was evaluated by western blotting. The 
histograms represent the mean±SEM of densitometric analysis of three independent experiments after normalization against β-actin. 
(Continued )
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Figure 8: (Continued ) (c) mRNA expression of IR-related transcription factors after DDR1 depletion. MCF-7 cells transfected 
as in (a) were evaluated by qRT-PCR analysis for IR, p53, HMGA, and Sp1 mRNA levels. Values were normalized using human β-actin 
as housekeeping control gene. DDR1 mRNA levels were also evaluated as control for DDR1 depletion efficiency. Values represent the 
mean±SEM of three independent experiments. (d) mRNA expression of IR-related transcription factors after DDR1 overexpression. In 
cells transfected as in (b), IR, p53, HMGA, and Sp1 mRNA levels were evaluated by qRT-PCR analysis and values were normalized 
using human β-actin as housekeeping control gene. DDR1 mRNA levels were also evaluated as silencing control. Values represent the 
mean±SEM of three independent experiments. (a-d) NS, p > 0.05; *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001. Statistical 
significance was calculated using Student’s t-test.
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it has been demonstrated that DDR1 is internalized after 
binding to different forms of collagen (collagen I, IV 
and VI) [16, 18, 28]. Herein, we found that DDR1 co-
internalization with IR is not dependent on collagen.
Remarkably, DDR1 modulates the two main 
signaling cascades downstream of the IR. DDR1 silencing 
significantly reduced the phosphorylation of both AKT and 
ERK1/2 in response to insulin and IGF-2, while DDR1 
overexpression enhanced it. According to these findings, 
DDR1 enhanced breast cancer cell proliferation, invasion 
and colony formation in response to insulin and IGF-2. 
Moreover, IR silencing abrogated the effect of DDR1 
overexpression on cell viability and invasion, not only 
in response to insulin and IGF-2 but also in unstimulated 
cells, indicating that IR expression was pivotal for the 
effects of DDR1.
We found that a major mechanism by which DDR1 
affects intracellular signaling and biological responses 
to insulin and IGF-2 is the modulation of IR expression. 
DDR1 affected IR expression at multiple levels by 
regulating both IR protein and mRNA half-life as well 
as transcription factors known to modulate IR gene 
expression [26, 27].
The decrease in IR protein levels induced by DDR1 
depletion was sensitive to inhibitors of the proteasome 
but not to lysosomal inhibition. Collectively, these 
results suggest that DDR1 may preferentially regulate 
the intracellular pool of IR protein degraded via the 
proteasome, but it does not affect IR turnover dependent 
on lysosomal degradation.
Ubiquitination of tyrosine-kinase receptors, 
including the IGF-1R and IR [29–34], plays an important 
Figure 9: DDR1 correlates with IR in human breast cancer datasets. Stratification analysis of DDR1 and IR correlative 
expression was performed. Pearson tests were calculated by separating the patients in clinical classes. This analysis was computed for 
GEO datasets gse21653 (Panel A), gse42568, gse76124 (Panel B). Black dots showed nine different combinations of Pearson test for three 
DDR1 probes (1007_s_at, 210749_x_at, 207169_x_at) and three IR probes (213792_s_at, 226450_at, 226216_at). Values plotted in the 
histograms are shown as –log10 of Pearson p-values. ER: estrogen receptor status; PR: progesterone receptor status; L: pathological lymph 
node status; Ki67: Ki-67 protein status evaluated by immunohistochemistry; pT: pathological tumor size; NB: normal breast tissue; PB: 
pathological breast tissue; G: grading of gse42568 datasets. G* grading of gse76124 datasets.
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role in regulating ligand-dependent receptor endocytosis 
and sorting for degradation. However, whether DDR1 
expression may affect IR ubiquitination remains to be 
elucidated. Further studies are required to fully clarify the 
molecular mechanisms associated with DDR1 action on 
IR trafficking and gene expression regulation.
IR overexpression and in particular IR-A isoform 
upregulation, as well as hyperinsulinemia and IGF-2, have 
a well-established role in breast cancer both in vitro and 
in vivo [1, 35–39]. Our data strongly suggest that DDR1 
might be an important determinant of IR overexpression 
in breast cancer. Significantly, we have previously shown 
that IGF-1, IGF-2 and insulin induce DDR1 upregulation 
in breast cancer cells by activating the AKT/miR199a-5b 
pathway [24]. Others have shown that DDR1 is one of the 
prominent molecules expressed by sarcomas characterized 
by constitutive IGF-2 overexpression [40]. Thus, the 
IR–DDR1 crosstalk constitutes a positive feedback loop 
enhancing the effects of insulin and IGF-2 in breast cancer 
cells.
These findings are consistent with previous data 
indicating that DDR1 as well as the IGF-2/IR-A loop are 
important regulators of prenatal growth [19] and cancer 
progression [20, 41].
By analyzing publicly available databases, we found 
that the correlation between DDR1 and IR is stronger in 
breast cancer specimens than in normal breast tissues. 
Importantly, the correlation between DDR1 and IR 
expression levels is even stronger in breast cancers with 
aggressive characteristics, such as basal-like phenotype, 
absence of estrogens and progesterone receptors, 
metastatic lymph-nodes, elevated Ki67 staining and tumor 
grading, confirming that this functional crosstalk might 
have important clinical implications in breast cancer. In 
this regard, our present finding that DDR1 affects both the 
AKT and the ERK1/2 pathways is particularly relevant, 
as IR/IGF-1R inhibitors proposed for cancer treatment are 
generally more effective in blocking the AKT pathway 
than inhibiting the ERK pathway, and may actually 
stimulate this pathway in certain models [42–44]. Thus, 
DDR1 may work as a possible novel candidate in targeting 
the IGF-2/IR-A loop in cancer.
In summary, this study demonstrates that DDR1 
associates with the IR, enhances the activation of IR 
downstream signaling and the mitogenic and pro-invasive 
effects of insulin and IGF-2 in breast cancer cells. 
DDR1 emerges as a novel and important regulator of IR 
expression by acting at multiple levels. All these effects 
are distinct from the previously characterized role of 
DDR1 as a collagen receptor. In accordance with these in 
vitro findings, DDR1 and IR expression levels are strongly 
correlated in breast cancer specimens, and especially in 
cancers with aggressive characteristics, suggesting that the 
DDR1 - IR axis could be a valuable therapeutic target in 
human breast cancer.
MATERIALS AND METHODS
Materials
Insulin and IGF-2 were purchased from 
Prepotech (Rocky Hill, NJ); bovine serum albumin 
(BSA), fibronectin, collagen Type IV, actinomycin D, 
cycloheximide, cloroquine, and MG132 from Sigma-
Aldrich (Saint Louis Missouri, USA); Metafectene 
PRO from Biontex Laboratories GmbH (Germany); 
lipofectamine RNAiMax, Opti-MEM, fetal calf serum 
(FCS), Geneticin (G-418), puromycin, TRIzol Reagent, 
ThermoScript RT kit, SYBR Green MasterMix from Life 
Technologies, Inc. Laboratories (Paisley, UK); MTT, 
nitrocellulose membranes, HRP-conjugated secondary 
antibodies from Amersham Biosciences (Little Chalfont, 
UK).
Table 1: Primers used for quantitative PCR
h-DDR1 total FW 5’-GCGTCTGTCTGCGGGTAGAG-3’RV 5’-ACGTCAGATAAATACATTGTCT-3’
h-IR FW 5’-CGTGGAGGATAATTACATCGTGTT-3’RV 5’-TGGTCGGGCAAACTTTCTG-3’
p53 FW 5’-CACTGCCCAACAACACCAGCTCCT-3’RV 5’-GTCTGAGTCAGGCCCTTCTGTCTT-3’
HMGA1a FW 5’-AGGAAAAGGACGGCACTGAGAA-3’RV 5’-CCCCGAGGTCTCTTAGGTGTTGG-3’
Sp1 FW 5’-TGAAAAAGGAGTTGGTGGC-3’RV 5’-TGCTGGTTCTGTAAGTTGGG-3’
h β-actin
FW 5’-GACAGGATGCAGAAGGAGATCACT-3’
RV 5’-TGATCCACATCTGCTGGAACC T-3’
Fw: forward; Rv: reverse
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Constructs encoding either an empty vector 
(pCMV6- EV) or the human wild type DDR1 isoform a 
(DDR1wt) cDNAs were from OriGene (Rockville, MD, 
USA). The specific silencer Select Pre-designed pool of 
four siRNA oligos for DDR1 (Human DDR1 siGENOME 
SMARTpool Cat M-003111–04) and the negative control, 
consisting of a pool of four scramble siRNAs were from 
Thermo Fisher Scientific Dharmacon (NYSE:TMO). 
Doxycicline inducible lentivirus vectors (pTZ) encoding 
for DDR1 cDNA or control vector GFP were purchased 
from GE Healthcare Dharmacon Europe.
Cell cultures
The human cancer cell lines MCF-7, BT-474, MDA-
MB-157, T47D, ZR-75, MDA-MB-231, MDA-MB-468 
were purchased from the American Cell Type Culture 
Collection and cultured according to the manufacturer’s 
instructions. Cells were grown in Medium supplemented 
with 10% fetal bovine serum (FBS).
Western blot analysis
Cell lysates were subjected to Western blot analysis 
as previously described [45]. The following antibodies 
were used: anti-DDR1 (C-20), anti-IRβ (C-19), anti-p53 
(DO-1), anti HMG-I/HMG-Y (FL-95) (Santa Cruz 
Biotechnology); anti-p-Akt (Ser473), anti-AKT, anti-p-
ERK1/2 (T202/Y204), anti-ERK1/2, anti-Sp1 (D4C3) 
(Cell Signaling Technology); anti-β-actin (Sigma-Aldrich, 
Saint Louis Missouri, USA).
Real-time PCR
Total cellular RNA was extracted using TRIzol 
Reagent according to the manufacturer’s protocol, as 
previously described [46]. qRT–PCR was used to confirm 
the expression levels of mRNAs. Total RNA (2μg) was 
reversely transcribed using the ThermoScript RT kit and 
oligo(dT) primers. Synthesized cDNA was combined in a 
qRT-PCR reaction using primers for the gene of interest 
(Table 1). The ΔΔCt method of relative quantification and 
SYBR Green chemistry were used to measure mRNA.
Confocal microscopy
MCF-7 cells were plated onto coverslips, serum 
starved for 24h, and then stimulated with either insulin or 
IGF-2. Coverslips were processed for immunofluorescence 
and confocal analysis at the Sidney Kimmel Cancer 
Center Bioimaging Core Facility, as previously described 
[23]. Primary antibodies used were: anti-IR (polyclonal 
antibody C-19, Santa Cruz Biotechnology), anti-DDR1 
(polyclonal antibody C-20, Santa Cruz Biotechnology). 
After incubation with primary antibodies, the coverslips 
were incubated using secondary antibodies, goat anti-
mouse IgG Alexa Fluor 488 (Invitrogen) and goat anti-
rabbit IgG Alexa Fluor 594 (Invitrogen). Coverslips 
were analyzed and photographed on a Nikon AIR 
inverted confocal microscope with a Plan-Apo 60x oil 
immersion lens at room temperature and NIS Elements C 
software. Images were analyzed using Image J. Pictures 
are representative of at least 10 independent fields from 
three independent experiments. Fields were selected for 
the presence of cells with the following criteria: well 
defined limits, clear identification of nucleus and absence 
of intersection with neighboring cells. An average of 
100 cells was examined for each condition. Data are 
representative of ~80% of the total number of cells 
examined. Co-localization index was calculated using NIH 
ImageJ software.
Immunoprecipitation analysis
Cells were lysed and processed as previously 
described [49]. The following antibodies were used for 
Immunoprecipation: anti-DDR1 (monoclonal antibody 
MAB2396, R&D System) and anti-HA.11 (monoclonal 
antibody 16B12, Covance). The following antibodies 
were used for Western Blotting: anti-DDR1 (policlonal 
antibody C-20, sc-532) and anti-IR (polyclonal antibody 
C-19, Santa Cruz biotechnology).
Gene silencing by small interfering RNA, and 
gene overexpression
For small interfering RNA (siRNA) experiments, 
cells were transiently transfected with a mixture containing 
OptiMem, Lipofectamine RNAiMax and either a pool of 
four scramble siRNA oligos (10nM) or a pool of four 
specific siRNA oligos for DDR1 (10nM).
For overexpression experiments, cells were 
transiently transfected with a mixture containing Opti-
Mem, Metafectene PRO and the DNA of interest or the 
corresponding control empty vectors.
Most experiments of DDR1 overexpression were 
performed by transiently transfecting cells with plasmids 
encoding either the human constitutive pCMV6-DDR1 
or the corresponding empty vector (pCMV6-EV). Cells 
were then processed after 48h, according to the aim 
of the experiment. As, a complementary approach to 
overexpress DDR1, cells were transiently transfected 
with a doxy-inducible pTZ-DDR1 lentiviral vector 
or control pTZ-GFP vector. Twenty-four hours after 
transfection, cells were incubated with doxycycline 
(1μg/mL) for 48h and then processed to perform the 
experiments of interest.
To evaluate the IR downstream signaling, transfected 
cells were serum starved for 24h, and stimulated with 
insulin (10nM) or IGF-2 (10nM) for 5 min.
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Cell viability
Cell viability was measured by the methyl thiazolyl 
tatrazolium (MTT) test. MCF-7, MDA-MB-157 and 
BT-474 cell lines were plated in 48-multiwell plates 
under standard culture conditions. After 24h, cells were 
transfected with a pool of four DDR1 siRNA oligos or 
DDR1 expressing vectors and the relative negative 
controls. After 24h, cells were serum-starved for 24h and 
then stimulated with insulin (10nM) or IGF-2 (10nM) 
for additional 48h. The cells were then incubated with 
medium containing 5mg/mL MTT and processed as 
previously described [47].
Invasion assay
The ability of cells to invade the extracellular 
matrix was measured with Boyden's chamber technique as 
described [23]. Cells, serum starved for 24h, were placed 
on polycarbonate filters (8μm pore size, Corning Costar) 
coated on the upper side with 25μg/mL fibronectin. Filters 
were placed over bottom chambers containing serum-free 
medium with or without ligand (10nM). After incubation 
for 6-8h, depending on the cell type, cells on the upper 
surface of filters were removed with a cotton swab, and 
the filters were stained for 30min with crystal violet 
(0.05% crystal violet in PBS plus 20% ethanol). After 
three washes with water, crystal violet was solubilized in 
10% acetic acid for 30min at room temperature, and its 
concentration was evaluated by absorbance at 595 nm.
Cell cycle evaluation
Cells synchronized for 24h in serum-free medium 
were exposed to insulin (10nM) or IGF-2 (10nM) for 
48h and subjected to fluorescence-activated cell sorting 
(FACS) analysis, as previously described [48].
Soft-agar colony formation assay
Anchorage-independent growth was assessed as 
previously described [23] with some modifications. 
Briefly, a mixture of 0.66% agar and medium containing 
2.5% of CS-FCS was plated on the bottom of each well 
plate (hard-agar). Then, cells suspended in 2.5% CS-FCS 
medium containing 0.33% agar (soft-agar) were plated on 
the top of the hard-agar layer. Top agar was then covered 
with culture medium with or without insulin (10nM) or 
IGF-2 (10nM). Stimulus was changed twice a week and 
cells were cultured for 3 weeks. Colonies were visualized 
with 0.5mg/mL MTT, photographed and analyzed with 
NIH ImageJ.
Analysis of expression correlation
The correlation of expression between DDR1 and 
IR across 32 different human datasets of microarray 
experiments was analyzed on breast cancer biopsies and 
cell lines. We selected from Gene Expression Omnibus 
(GEO) (https://www.ncbi.nlm.nih.gov/geo) the Affymetrix 
GeneChip Human Genome U133A and U133 plus 2.0 
arrays normalized by MAS5.0 algorithm. We computed 
the Pearson correlation and p-value between DDR1 and IR 
for each dataset considered. The Pearson value provides 
an index of positive expression correlation between two 
genes when it is positive, otherwise, negative expression 
correlation when it is negative. Multiple probes of DDR1 
and IR transcripts were assayed in the Affymetrix chips 
analysis. Therefore, we separately calculated the Pearson 
value of three probes for DDR1 and three probes for 
IR. For GEO datasets showing a persistent statistically 
significant positive correlation between DDR1 and IR for 
each combination of probes, we performed a stratification 
analysis by separating the datasets into clinical categories 
and iterating the Pearson analysis. GEO ID of datasets and 
probes are reported in Supplementary Table 1.
Densitometric and statistical analysis
Densitometry results were obtained by using NIH 
ImageJ. Differences between means were evaluated 
by one-way ANOVA followed by post-hoc analysis 
of significance (Bonferroni test) for the comparison 
between more than two groups, whereas the Student’s 
t test for unpaired samples was used for comparisons 
between two groups. The level of significance was set at 
p<0.05. Statistical analysis was performed with GraphPad 
Prism6 (GraphPad Software, San Diego, CA). Data were 
expressed as mean±SEM.
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